Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
12 p, 435.5 KB Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts / Bang, Yung-Jue (Seoul National University College of Medicine) ; Su, Wu-Chou (National Cheng Kung University Hospital) ; Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ; Nam, Do-Hyun (Samsung Medical Center) ; Lim, Wan Teck (National Cancer Centre) ; Bauer, Todd M. (PLLC) ; Azaro, Analia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Poon, Ronnie Tung Ping (Queen Mary Hospital) ; Hong, David (University of Texas/MD Anderson Cancer Center) ; Lin, Chia-Chi (National Taiwan University Hospital) ; Akimov, Mikhail (Novartis Pharma AG) ; Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ; Zhao, Sylvia (China Novartis Institutes for BioMedical Research) ; Giovannini, Monica (Novartis Pharmaceuticals Corporation) ; Ma, Brigette (The Chinese University of Hong Kong)
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose expansion in advanced non-lung tumors. [...]
2019 - 10.1111/cas.14254
Cancer Science, Vol. 111 (december 2019) , p. 536-547  
11 p, 542.8 KB A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer / Reynolds, Kerry Lynn ; Bedard, Philippe L. (Toronto, ON Canada) ; Lee, Se-Hoon (Seoul, Republic of Korea) ; Lin, Chia-Chi (Taipei, Taiwan) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Alsina, Maria (Hospital Universitari Vall d'Hebron) ; Cohen, Ezra (La Jolla, CA USA) ; Baselga Torres, Josep, 1959-2021, (New York, NY USA) ; Blumenschein, George (Houston, TX USA) ; Graham, Donna M. (Toronto, ON Canada) ; Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ; Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ; Sharma, Sunil (Salt Lake City, UT USA) ; Salgia, Ravi (Duarte, CA USA) ; Seroutou, Abdelkader (Basel, Switzerland) ; Tian, Xianbin (East Hanover, NJ USA) ; Fernandez, Rose (East Hanover, NJ USA) ; Morozov, Alex (New York, NY USA) ; Sheng, Qing (Cambridge, MA USA) ; Ramkumar, Thiruvamoor (East Hanover, NJ USA) ; Zubel, Angela (Basel, Switzerland) ; Bang, Yung-Jue (Seoul, Republic of Korea) ; Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)  

Vea también: autores con nombres similares
8 Lin, C.
2 Lin, C. S.
2 Lin, C. Y.
1 Lin, C.J.F.
6 Lin, C.S.
88 Lin, C.Y.
1 Lin, Celia Jow Fang
1 Lin, Charles Y.
1 Lin, Chi-lien
2 Lin, Chin-Cheng
2 Lin, Christopher C.H.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.